Respiratory Syncytial Virus Infections Concept

subject area of

• A Comparison of Respiratory Syncytial Viral Prophylaxis in Multiple Births versus Singletons in the Canadian Registry of Palivizumab  Academic Article
• A Decade of Respiratory Syncytial Virus Epidemiology and Prophylaxis: Translating Evidence into Everyday Clinical Practice  Academic Article
• A Survey of Parental Knowledge of Respiratory Syncytial Virus and Other Respiratory Infections in Preterm Infants  Academic Article
• A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS)  Academic Article
• A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection  Academic Article
• A new cost-utility analysis assessing risk factor-guided prophylaxis with palivizumab for the prevention of severe respiratory syncytial virus infection in Italian infants born at 29–35 weeks’ gestational age  Academic Article
• A review of cost–effectiveness of palivizumab for respiratory syncytial virus  Academic Article
• Absence of detection of RSV and influenza during the COVID-19 pandemic in a Brazilian cohort: Likely role of lower transmission in the community  Academic Article
• Achieving control of asthma in preschoolers  Academic Article
• Adherence and outcomes: a systematic review of palivizumab utilization  Academic Article
• Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab  Academic Article
• Adoption in Canada of an international risk scoring tool to predict respiratory syncytial virus hospitalization in moderate-to-late preterm infants  Academic Article
• Are late preterm infants as susceptible to RSV infection as full term infants?  Academic Article
• Association of Respiratory Viruses with Outcomes of Severe Childhood Pneumonia in Botswana  Academic Article
• Burden of Severe Respiratory Syncytial Virus Disease Among 33–35 Weeks’ Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons  Academic Article
• Burden of respiratory syncytial virus hospitalisation among infants born at 32–35 weeks' gestational age in the Northern Hemisphere: pooled analysis of seven studies  Academic Article
• Burden of respiratory syncytial virus infection in community-dwelling older adults in Europe (RESCEU): an international prospective cohort study  Academic Article
• CARESS  Academic Article
• CARESS: The Canadian Registry of Palivizumab  Academic Article
• Challenges in the prevention or treatment of RSV with emerging new agents in children from low- and middle-income countries  Academic Article
• Changing costs and the impact on RSV prophylaxis  Academic Article
• Characteristics and Outcomes of Young Children Hospitalized With Laboratory-confirmed Influenza or Respiratory Syncytial Virus in Ontario, Canada, 2009-2014.  Academic Article
• Characteristics and Outcomes of Young Children Hospitalized With Laboratory-confirmed Influenza or Respiratory Syncytial Virus in Ontario, Canada, 2009–2014  Academic Article
• Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis  Academic Article
• Comparing First- and Second-year Palivizumab Prophylaxis in Patients With Hemodynamically Significant Congenital Heart Disease in the CARESS Database (2005–2015)  Academic Article
• Comparison of Flocked and Rayon Swabs for Collection of Respiratory Epithelial Cells from Uninfected Volunteers and Symptomatic Patients  Academic Article
• Comparison of Viral Isolation and Multiplex Real-Time Reverse Transcription-PCR for Confirmation of Respiratory Syncytial Virus and Influenza Virus Detection by Antigen Immunoassays  Academic Article
• Comparison of the Cost of Hospitalization for Respiratory Syncytial Virus Disease Versus Palivizumab Prophylaxis in Canadian Inuit Infants  Academic Article
• Cost-effectiveness of respiratory syncytial virus prophylaxis in premature infants less than 32 weeks gestational age in Turkey.  Academic Article
• Current strategies in the prevention of respiratory syncytial virus disease  Academic Article
• Development and Validation of a Risk Scoring Tool to Predict Respiratory Syncytial Virus Hospitalization in Premature Infants Born at 33 through 35 Completed Weeks of Gestation  Academic Article
• Development of a Sensitive Loop-Mediated Isothermal Amplification Assay That Provides Specimen-to-Result Diagnosis of Respiratory Syncytial Virus Infection in 30 Minutes  Academic Article
• Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus  Academic Article
• Does prophylaxis with palivizumab reduce hospitalisation rates for respiratory-syncytial-virus-related infection in cystic fibrosis children less than 2 years of age?  Academic Article
• Economic Burden and Health-Related Quality of Life of Respiratory Syncytial Virus and Influenza Infection in European Community-Dwelling Older Adults  Academic Article
• Estimating the Incidence of First RSV Hospitalization in Children Born in Ontario, Canada  Academic Article
• Expert consensus on palivizumab use for respiratory syncytial virus in developed countries  Academic Article
• Exploring respiratory syncytial virus prophylaxis for children with all grades of bronchopulmonary dysplasia  Academic Article
• First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005–2015)  Academic Article
• Global molecular diversity of RSV – the “INFORM RSV” study  Academic Article
• Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series  Academic Article
• High risk for RSV bronchiolitis in late preterms and selected infants affected by rare disorders: a dilemma of specific prevention  Academic Article
• Hospitalization for Respiratory Syncytial Virus Illness in Down Syndrome Following Prophylaxis With Palivizumab  Academic Article
• Hospitalization for Respiratory Syncytial Virus in Children with Down Syndrome Less than 2 Years of Age: A Systematic Review and Meta-Analysis  Academic Article
• Identifying and Ensuring Optimal Care for All Children at Risk of Developing Serious Respiratory Syncytial Virus Disease: A Canadian Nurses’ Perspective  Academic Article
• Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants  Academic Article
• Increased Risk of RSV Infection in Children with Down's Syndrome: Clinical Implementation of Prophylaxis in the European Union  Academic Article
• Interactions of viral pathogens on hospital admissions for pneumonia, croup and chronic obstructive pulmonary diseases: results of a multivariate time-series analysis  Academic Article
• Lower respiratory infections in early life are linked to later asthma  Academic Article
• Molecular Evolution of Respiratory Syncytial Virus Fusion Gene, Canada, 2006–2010  Academic Article
• Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data  Academic Article
• Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy  Academic Article
• Palivizumab Adherence and Outcomes in Canadian Aboriginal Children  Academic Article
• Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes  Academic Article
• Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?  Academic Article
• Pediatric Investigators Collaborative Network on Infections in Canada Study of Respiratory Syncytial Virus–associated Deaths in Pediatric Patients in Canada, 2003–2013  Academic Article
• Performance Assessment of a Rapid Molecular Respiratory Syncytial Virus Point-of-Care Test: A Prospective Community Study in Older Adults  Academic Article
• Performance and ease of use of a molecular point-of-care test for influenza A/B and RSV in patients presenting to primary care  Academic Article
• Practical Resources for Nurses and Other Health Care Providers Involved in the Care of Children at Risk for Respiratory Syncytial Virus Infection  Academic Article
• Predictive value of the respiratory syncytial virus risk-scoring tool in the term infant in Canada  Conference Paper
• Predictors of Poor Outcomes Among Infants With Respiratory Syncytial Virus–associated Acute Lower Respiratory Infection in Botswana  Academic Article
• Prioritising respiratory syncytial virus prevention in low-income and middle-income countries  Academic Article
• Re: “Completed Weeks of Gestation and Risk of Respiratory Syncytial Virus in Late Preterm Infants”  Academic Article
• Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection.  Academic Article
• Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada  Academic Article
• Respiratory Syncytial Virus Preterm (32–36 Completed Weeks of Gestation) Risk Estimation Measure for RSV Hospitalization in Ireland  Academic Article
• Respiratory Syncytial Virus Prophylaxis in Down Syndrome: A Prospective Cohort Study  Academic Article
• Respiratory Syncytial Virus Prophylaxis in Immunocompromised Children  Academic Article
• Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005–2017  Academic Article
• Respiratory Syncytial Virus Prophylaxis in Neurologic and Muscular Disorders in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab  Academic Article
• Respiratory Syncytial Virus in Otherwise Healthy Prematurely Born Infants: A Forgotten Majority  Academic Article
• Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations  Academic Article
• Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab  Academic Article
• Respiratory syncytial virus (RSV) infection in children with medical complexity  Academic Article
• Respiratory syncytial virus and influenza virus infection in adult primary care patients: Association of age with prevalence, diagnostic features and illness course  Academic Article
• Respiratory syncytial virus nosocomial outbreak in neonatal intensive care: A review of the incidence, management, and outcomes  Academic Article
• Respiratory syncytial virus prophylaxis for children with chronic lung disease: have we got the criteria right?  Academic Article
• Respiratory syncytial virus prophylaxis in children with cardiac disease: a retrospective single-centre study  Academic Article
• Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005–2016)  Academic Article
• Respiratory syncytial virus prophylaxis in infants with congenital airway anomalies compared to standard indications and complex medical disorders  Academic Article
• Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005–2012) Compared to Other International Registries  Academic Article
• Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention  Academic Article
• Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants  Academic Article
• Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33–35 completed weeks’ gestational age in Canada  Academic Article
• Seasonal Respiratory Syncytial Virus Prophylaxis Based on Predetermined Dates Versus Regional Surveillance Data  Academic Article
• Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention  Academic Article
• Simultaneous Viral Whole-Genome Sequencing and Differential Expression Profiling in Respiratory Syncytial Virus Infection of Infants  Academic Article
• Special populations: Do we need evidence from randomized controlled trials to support the need for respiratory syncytial virus prophylaxis?  Academic Article
• Strategies for Reducing the Risk of Respiratory Syncytial Virus Infection in Infants and Young Children: A Canadian Nurses’ Perspective  Academic Article
• The Pediatric Investigators Collaborative Network on Infections in Canada Study of Predictors of Hospitalization for Respiratory Syncytial Virus Infection for Infants Born at 33 Through 35 Completed Weeks of Gestation  Academic Article
• The Real-Life Effectiveness of Palivizumab for Reducing Hospital Admissions for Respiratory Syncytial Virus in Infants Residing in Nunavut  Academic Article
• The cost effectiveness of palivizumab in congenital heart disease: a review of the current evidence  Academic Article
• The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic  Academic Article
• The cost effectiveness of palivizumab: a systematic review of the evidence  Academic Article
• The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32–35 weeks: a Canadian-based analysis  Academic Article
• The impact of prophylaxis on paediatric intensive care unit admissions for RSV infection: a retrospective, single-centre study  Academic Article
• Third human challenge trial conference, Oxford, United Kingdom, February 6–7, 2020, a meeting report  Academic Article
• Value of a risk scoring tool to predict respiratory syncytial virus disease severity and need for hospitalization in term infants  Academic Article
• Viral infections in the elderly  Academic Article
• World Health Organization Influenza-Like Illness Underestimates the Burden of Respiratory Syncytial Virus Infection in Community-Dwelling Older Adults  Academic Article